Thiol-activated hydrogen sulfide donors antiviral and anti-inflammatory activity in respiratory syncytial virus infection

Nikolay Bazhanov, Teodora Ivanciuc, Haotian Wu, Matteo Garofalo, Jianming Kang, Ming Xian, Antonella Casola

Research output: Contribution to journalArticle

2 Scopus citations


We have recently shown that endogenous hydrogen sulfide (H2S), an important cellular gaseous mediator, exerts an antiviral and anti-inflammatory activity in vitro and in vivo, and that exogenous H2S delivered via the synthetic H2S-releasing compound GYY4137 also has similar properties. In this study, we sought to extend our findings to a novel class of H2S donors, thiol-activated gem-dithiol-based (TAGDDs). In an in vitro model of human respiratory syncytial virus (RSV) infection, TAGDD-1 treatment significantly reduced viral replication, even when added up to six hours after infection. Using a mouse model of RSV infection, intranasal delivery of TAGDD-1 to infected mice significantly reduced viral replication and lung inflammation, markedly improving clinical disease parameters and pulmonary dysfunction, compared to vehicle treated controls. Overall our results indicate that this novel synthetic class of H2S-releasing compounds exerts antiviral and anti-inflammatory activity in the context of RSV infection and represents a potential novel pharmacological approach to ameliorate viral-induced lung disease.

Original languageEnglish (US)
Article number249
Issue number5
StatePublished - May 10 2018



  • Airway inflammation
  • Hydrogen sulfide donor
  • Mouse model
  • Respiratory syncytial virus

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this